JOM KITA KE POLITEKNIK

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study (Record no. 2221)

MARC details
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Donovan, Killian
Relator term author
9 (RLIN) 3106
245 00 - TITLE STATEMENT
Title Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2023-01-01.
500 ## - GENERAL NOTE
General note /pmc/articles/PMC7614195/
500 ## - GENERAL NOTE
General note /pubmed/36719157
520 ## - SUMMARY, ETC.
Summary, etc. BACKGROUND: Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding. METHODS: SCALLOP consortium data on 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically-predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease (n=26,266 events), of any non-atherosclerotic cardiovascular disease (n=12,652), and of non-cardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n=181,249 cases), MEGASTROKE (stroke, n=34,217), and HERMES (heart failure, n=47,309). RESULTS: We identified 34 independent variants for circulating FGF-23 which formed a validated genetic score. There were no associations between genetically-predicted FGF-23 and any of the cardiovascular or non-cardiovascular outcomes. In UK Biobank, the odds ratio for any atherosclerotic cardiovascular disease per 1-SD higher genetically-predicted logFGF-23 was 1.03 (95% confidence interval [CI] 0.98-1.08), and for any non-atherosclerotic cardiovascular disease was 1.01 (0.94-1.09). The odds ratios in the case-control consortia were 1.00 (0.97-1.03) for coronary artery disease, 1.01 (0.95-1.07) for stroke, and 1.00 (0.95-1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalties. CONCLUSION: Genetically predicted FGF-23 levels are not associated atherosclerotic and non-atherosclerotic cardiovascular diseases, suggesting no important causal link.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction https://creativecommons.org/licenses/by/4.0/Open Access For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising. (https://creativecommons.org/licenses/by/4.0/)
546 ## - LANGUAGE NOTE
Language note en
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Article
655 7# - INDEX TERM--GENRE/FORM
Genre/form data or focus term Text
Source of term local
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Herrington, William G.
Relator term author
9 (RLIN) 2196
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Paré, Guillaume
Relator term author
9 (RLIN) 3107
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Pigeyre, Marie
Relator term author
9 (RLIN) 3108
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Haynes, Richard
Relator term author
9 (RLIN) 2234
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Sardell, Rebecca
Relator term author
9 (RLIN) 3109
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Butterworth, Adam S.
Relator term author
9 (RLIN) 3110
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Folkersen, Lasse
Relator term author
9 (RLIN) 3111
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Gustafsson, Stefan
Relator term author
9 (RLIN) 3112
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Wang, Qin
Relator term author
9 (RLIN) 3113
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Baigent, Colin
Relator term author
9 (RLIN) 2233
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Mälarstig, Anders
Relator term author
9 (RLIN) 3114
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Holmes, Michael V.
Relator term author
9 (RLIN) 3115
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Staplin, Natalie
Relator term author
9 (RLIN) 2197
786 0# - DATA SOURCE ENTRY
Note Clin J Am Soc Nephrol
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.2215/CJN.05080422">http://dx.doi.org/10.2215/CJN.05080422</a>
Public note Connect to this object online.

No items available.